At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
In Brief
A Phase 2 clinical trial evaluating Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, and 2 other interventions for Carcinoid Syndrome and Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm. Completed, enrolled 4 participants across 1 site.
Detailed Summary
This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying the changes within the tumor cells via AMT-PET may help doctors better understand how tumors respond to treatment with telotristat etiprate.
Study Details
Timeline
Interventions
Undergo AMT-PET
Correlative studies
Undergo AMT-PET
Given PO